Since the discovery of the production of mouse monoclonal antibodies (mABs) using hybridoma technology 47 years ago, much interest had been generated in the use of mAB for therapeutics such as transplantation, oncology, autoimmune, cardiovascular and infectious diseases.

Increased efforts have been put into research and development since then to improve the productivity, efficiency and consistency of the mAB manufacturing process. Today, over 100 monoclonal antibodies have been designated as drugs for the treatment of immunologic diseases, reversal of drug effects and cancer therapy.

Have you ever wondered how mABs are first generated? How are they subsequently being evaluated and produced at large scale? What are the steps involved to manufacture them successfully? Join us in this webinar to learn more about mABs, how they are developed at small scale and how they can be brought to commercialization.